Kairos Pharma, Ltd. (KAPA)
Rating: Buy

Joseph Pantginis, Ph.D.
646-975-6968
jpantginis@hcwresearch.com

Sara Nik, Ph.D.
212-916-3970
snik@hcwresearch.com

Matthew Keller, Ph.D.
212-856-5745
mkeller@hcwresearch.com

Lander Egaña Gorroño, Ph.D.
212-916-3977
legana@hcwresearch.com

Joshua Korsen, Ph.D.
212-715-2886
jkorsen@hcwresearch.com

Strategic Acquisition Bridges the Gap to High-Value Oncology Combination Therapy; 2025 Results

Stock Data	4/1/2026
Price	$0.58
Exchange	NASDAQ
Price Target	$12.00
52-Week High	$2.11
52-Week Low	$0.40
Enterprise Value (M)	$8
Market Cap (M)	$12
Shares Outstanding (M)	21.4
3 Month Avg Volume	518,265
Short Interest (M)	0.20
Balance Sheet Metrics	
Cash (M)	$4.5
Total Debt (M)	$0.1
Total Cash/Share	$0.21

EPS ($) Diluted			
Full Year - Dec	2025A	2026E	2027E
1Q	(0.08)	(0.07)	--
2Q	(0.08)	(0.08)	--
3Q	(0.07)	(0.09)	--
4Q	(0.07)	(0.12)	--
FY	(0.30)	(0.38)	(0.67)

Revenue ($M)			
Full Year - Dec	2025A	2026E	2027E
1Q	0.0	0.0	--
2Q	0.0	0.0	--
3Q	0.0	0.0	--
4Q	0.0	0.0	--
FY	0.0	0.0	0.0

Public statements available from 3Q24

Our perspective on strategic acquisitions:

- We view the acquisition of two differentiated, clinical stage oncology assets from Celyn Therapeutics (private) as a smart strategic move, bolstering the pipeline in NSCLC.
- The asset acquisition from an OrbiMed-backed entity (Celyn) provides institutional validation and helps to de-risk the platform, in our belief.
- This move transitions the company from a single-asset story into a diversified oncology platform, with a clear focus on the oncology drug resistance space.

Acquisition of Phase 1 ready NSCLC assets bolsters fight against drug resistance. Recently, Kairos announced the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics (private). Under the proposed terms of the agreement, Kairos will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. Kairos acquired worldwide right for both assets for all indications for an upfront payment of 16.5% fully-diluted capital stock, milestone payments (including a $15 million payment at NDA/BLA filing for CL-273) and 2% royalties from net revenue generated from sales n the U.S. We note that while the transaction adds both CL-273 and CL-741, the $15 million clinical milestone is specifically tied to the regulatory progress of the lead asset CL-273. This transaction pivots the company into the high-stakes $16.2 billion EGFR-mutated lung cancer market and introduces a top institutional backer (OrbiMed) to the cap table. We view this transaction as a positive development for the company, clearing two important hurdles, pipeline depth and institutional credibility. Taken together, we think this transaction provides a meaningful validation and strategic pipeline synergy to the existing Kairos portfolio of assets, which we outline in further detail below. Two assets addressingEGFR and MET-driven resistance pathways in lung cancer provides a meaningful complement to its existing Phase 1 program for ENV-105 in EGFR-mutated NSCLC, in our belief. Upcoming milestones to monitor include:

- **ENV105:** Continued progress in Phase 1 trials for cancer immunotherapy.
- **CL-273 (pan-EGFR mutant inhibitor):** IND filing is expected in 2Q26 with initiation of a Phase 1 study shortly thereafter.
- **CL-741 (c-MET inhibitor):** A Phase 1 study is expected to start by YE26.

Two new assets addressing resistance mechanisms in oncology. The Celyn assets are engineered to address the specific failure points of AstraZeneca's (AZN; not rated) Tagrisso (osimertinib) and the shortcomings of first-generation MET inhibitors like Savolitinib. The transaction allows Kairos to target the two most common resistance mechanisms to AstraZeneca's Tagrisso (osimertinib), C797S mutations and MET amplification.

New Assets Addressing Resistance Mechanisms



Source: Company materials

EGFR inhibitors (TKI) are generally effective against exon 19 deletion and exon 21 L858R mutations, however there are significant side effects. CL-273 (KROS-273) is designed as a non-covalent and reversible inhibitor, targeting actionable mutations including insertions, deletions and mutations for exon 20, exon 19 and PACC mutations, with an improved safety profile due to > 100x selectivity against wtEGFR.

4th generation pan-EGFR inhibitor – CL-273 (KROS-273)

Drug	Modality	Development Stage	Key Attributes	Company
Amivantamab	EGFR/MET bispecific antibody	Marketed (1L + 2L)	First-line with chemo; strong PFS; EGFR/MET targeting	Johnson & Johnson
Mobocertinib	Oral irreversible TKI	Marketed (2L)	ORR ~30%; notable EGFR WT toxicity	Takeda
Firmonertinib	Next-gen oral TKI	Phase 3	Demonstrated activity in PACC mutants	ArriVent
Sunvozertinib	Selective oral TKI	Phase 2 / Conditional Approval (China)	Selective exon 20 coverage; favorable safety, 30-40% ORR in lung	Dizal Pharma
Zipalertinib	Selective oral TKI	Phase 3	Broad activity; 30-40% ORR in lung	Cullinan Oncology / Taiho
Zoldonrasib	Selective oral TKI	Phase 2	Broad activity; 36-42% ORR in lung	Black Dimond Therapeutics
KROS-273	**Best-in-class oral, pan-EGFR TKI**	**IND-Enabling**	**Mutant selective, strong lung data**	**Kairos**

Source: Company materials

Best in class cMET inhibitor – CL-741 (KROS-741)

	Capmatinib	Tepotinib	Cabozantinib	KROS-741
Plasma Free Fraction	4%	2%	0.2%	3%
Total plasma concentration needed to cover c-Met WT EC_{50}	40 ng/mL (3.2 nM)[1]	525 ng/mL (19.2 nM)[1]	26,600 ng/mL (53.3 nM)[2]	230 ng/mL (13.6 nM)[1]
Clinical daily dose	400 mg X 2	450 mg	60 mg	100 mg X 2[6]
Clinical plasma C_{ave} at SS	~1800 ng/mL[3]	~1100 ng/mL[4]	~1000 ng/mL[5]	250 ng/mL[6]
Clinical plasma C_{ave} over c-Met WT EC_{50}	45x	2x	70-130x	1x
ORR	44%-67%	45%	10%	–
PFS	9.7 - 12.3 mo	8.5 mo	3.5 mo	–

Source: Company materials

The CL-741 (KROS-741) Phase 1 trial architecture is designed as a dose-to-expansion study, transitioning from safety escalation to specific indication-driven cohorts across lung and liver cancers. By targeting baseline MET amplification alongside acquired resistance, KAPA is positioning CL-741 to move into the $16.2B first-line (1L) market rather than remaining a pure salvage therapy. The trial is structured to quickly establish a Recommended Phase 2 Dose (RP2D) before expanding into high-conviction resistance niches. The inclusion of a Liver Cancer cohort (Atezolizumab/Bevacizumab-resistant) significantly expands the TAM beyond NSCLC. MET alterations drive multiple solid tumors, including gastric and renal cancer, suggesting that if the Phase 1 dose-escalation is successful, the company could potentially initiate basket trials across several multi-billion dollar indications.

cMET inhibitor – CL-741 (KROS-741) trial design



Source: Company materials

Financial update. Kairos reported 4Q25 and 2025 full year financial results, posting EPS of ($0.07) and ($0.30), respectively, compared to our estimates of ($0.14) and ($0.29). The company ended the year with $4.491 million in cash.

Valuation and Risks. We reiterate our Buy rating and $12 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. We consider two key factors when considering our valuation of Kairos using our NPV approach:

- We only value ENV-105 for mCRPC for the U.S. market (20% PoS 100% contribution), which has the potential to be a blockbuster indication for Kairos. We feel we are being conservative in our market model approach of ENV-105 by only attaining ~20% market penetration and ~$700 million peak sales, while still representing an unmet medical need.
- We purposely omit the rest of Kairos' pipeline, including ENV-105 for NSCLC, which is already in the clinic. This represents a not only an additional layer of conservatism, but provides significant upside potential over the long-term by having multiple opportunities increasing the changes of potential success, in our belief.

Factors that could impede the stock from reaching our price target include failed or inconclusive clinical trials, the inability of the company to secure adequate funding to progress its drug through the development pathway or the occurrence of dilutive capital raises.

($ in millions except per share data)

Profit & Loss	2022A	2023A	2024A	2025A	2026E	2027E	2028E
Licensing and R&D revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Milestone revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Product and Royalties	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Revenues	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
CoGS	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Profit	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
Gross margin	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*
G&A	0.5	1.6	1.9	3.4	4.4	8.3	13.2
R&D	0.1	0.1	0.4	2.1	4.5	10.1	19.2
Other op ex	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	**(0.6)**	**(1.7)**	**(2.3)**	**(5.6)**	**(8.8)**	**(18.4)**	**(32.4)**
EBIT margin	*nm*	*nm*	*nm*	*nm*	*nm*	*nm*	*nm*
Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortization Intangibles	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	**(0.6)**	**(1.7)**	**(2.3)**	**(5.6)**	**(8.8)**	**(18.4)**	**(32.4)**
EBITDA margin	*nm*	*nm*	*nm*	*nm*	*nm*	*nm*	*nm*
Non operating expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Interest Income/Other	0.0	0.0	0.0	0.1	0.1	0.3	0.3
Interest expense	0.5	0.1	0.3	0.0	0.0	0.0	0.0
EBT	**(1.1)**	**(1.8)**	**(2.6)**	**(5.4)**	**(8.8)**	**(18.0)**	**(32.1)**
EBT margin	*nm*	*nm*	*nm*	*nm*	*nm*	*nm*	*nm*
Provision for taxes	0.0	0.0	0.0	0.0	0.0	0.0	(8.0)
Net Income	**(1.1)**	**(1.8)**	**(2.6)**	**(5.4)**	**(8.8)**	**(18.0)**	**(32.1)**
Participation of preferred stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income to common	**(1.1)**	**(1.8)**	**(2.6)**	**(5.4)**	**(8.8)**	**(18.0)**	**(24.1)**
net margin	*nm*	*nm*	*nm*	*nm*	*nm*	*nm*	*nm*
Number of shares - basic	10.2	10.4	11.4	18.4	23.3	27.0	33.0
Number of shares - diluted	10.2	10.4	11.4	18.4	23.3	27.0	33.0
EPS - basic	**(0.1)**	**(0.17)**	**(0.23)**	**(0.30)**	**(0.38)**	**(0.67)**	**(0.73)**
EPS - diluted	**(0.1)**	**(0.17)**	**(0.23)**	**(0.30)**	**(0.38)**	**(0.67)**	**(0.73)**

Source: SEC filings and H.C. Wainwright estimates.

Joseph Pantginis, Ph.D. jpantginis@hcwco.com

IPO September 16, 2024

Quarterly P&L

	Q1'25A	Q2'25A	H1'25A	Q3'25A	9M'25A	Q4'25A	FY'25A	Q1'26E	Q2'26E	H1'26E	Q3'26E	9M'26E	Q4'26E	FY'26E
Licensing and R&D revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.0
Milestone revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.0
Product and Royalties	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.0
Other revenues	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.0
Revenues	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.0**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.0**
CoGS	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.0
Gross Profit	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.0**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.0**
Gross margin	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*
G&A	0.77	0.96	1.73	0.83	2.56	0.88	3.4	0.90	0.95	1.85	1.10	2.95	1.40	4.4
R&D	0.49	0.50	0.99	0.61	1.60	0.54	2.1	0.70	0.90	1.60	1.20	2.80	1.69	4.5
Other op ex	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.0
EBITDA	**(1.3)**	**(1.5)**	**(2.7)**	**(1.4)**	**(4.2)**	**(1.4)**	**(5.6)**	**(1.6)**	**(1.9)**	**(3.5)**	**(2.3)**	**(5.8)**	**(3.1)**	**(8.8)**
EBITDA margin							*nm*							*nm*
Non operating expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.0
Net Interest Income/Other	0.00	0.03	0.04	0.04	0.08	0.05	0.1	0.02	0.02	0.04	0.02	0.06	0.02	0.1
Interest expense	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.0
EBT	**(1.3)**	**(1.4)**	**(2.7)**	**(1.4)**	**(4.1)**	**(1.4)**	**(5.4)**	**(1.6)**	**(1.8)**	**(3.4)**	**(2.3)**	**(5.7)**	**(3.1)**	**(8.8)**
EBT margin							*nm*							*nm*
Provision for taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.0
Participation of preferred stock							0.0							0.0
Net Income to common	**(1.3)**	**(1.4)**	**(2.7)**	**(1.4)**	**(4.1)**	**(1.4)**	**(5.4)**	**(1.6)**	**(1.8)**	**(3.4)**	**(2.3)**	**(5.7)**	**(3.1)**	**(8.8)**
net margin							*nm*							*nm*
NoSH	15.88	17.21	16.54	20.21	17.76	20.42	18.43	21.41	22.10	21.76	24.30	22.60	25.20	23.25
NoSH	15.88	17.21	16.54	20.21	17.76	20.42	18.43	21.41	22.10	21.76	24.30	22.60	25.20	23.25
EPS - basic	**(0.08)**	**(0.08)**	**(0.16)**	**(0.07)**	**(0.23)**	**(0.07)**	**(0.30)**	**(0.07)**	**(0.08)**	**(0.16)**	**(0.09)**	**(0.25)**	**(0.12)**	**(0.38)**
EPS - diluted	**(0.08)**	**(0.08)**	**(0.16)**	**(0.07)**	**(0.23)**	**(0.07)**	**(0.30)**	**(0.07)**	**(0.08)**	**(0.16)**	**(0.09)**	**(0.25)**	**(0.12)**	**(0.38)**

Source: SEC filings and H.C. Wainwright estimates.

Joseph Pantginis, Ph.D. jpantginis@hcwco.com

IPO September 16, 2024

Important Disclaimers

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

RETURN ASSESSMENT

Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the common stock of companies within the same sector.

Market Perform (Neutral): The common stock of the company is expected to mimic the performance of a passive index comprised of all the common stock of companies within the same sector.

Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of all the common stock of companies within the same sector.

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

Distribution of Ratings Table as of April 1, 2026

			IB Service/Past 12 Months	
Ratings	Count	Percent	Count	Percent
Buy	580	87.09%	170	29.31%
Neutral	61	9.16%	10	16.39%
Sell	1	0.15%	0	0.00%
Under Review	24	3.60%	4	16.67%

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.

I, Joseph Pantginis, Ph.D., Sara Nik, Ph.D., Matthew Keller, Ph.D., Lander Egaña Gorroño, Ph.D. and Joshua Korsen, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Kairos Pharma, Ltd. (including, without limitation, any option, right, warrant, future, long or short position).

As of March 31, 2026 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Kairos Pharma, Ltd..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Kairos Pharma, Ltd. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did not receive compensation from Kairos Pharma, Ltd. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in Kairos Pharma, Ltd. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request.

H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.

H.C. Wainwright & Co., LLC's and its affiliates' salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.